

## **Pulmonary Function Tests in Type 2 Diabetes Mellitus and Their Association with Glycemic Control and Duration of the Disease**

**Kailash Charel<sup>1</sup>, Mukesh Singh Tomar<sup>2</sup>, Poonam Motwani<sup>3</sup>**

<sup>1</sup>Ex-Senior Resident, Department of Medicine, Gandhi Medical College, Bhopal, M.P

<sup>2</sup>MD Medicine, General Physician

<sup>3</sup>Junior Resident, Department of Physiology, Gajra Raja Medical College, Gwalior

---

Received: 25-06-2022 / Revised: 25-07-2022 / Accepted: 10-08-2022

Corresponding author: Dr Mukesh Singh Tomar

Conflict of interest: Nil

---

### **Abstract**

**Background:** Pulmonary complications of diabetes mellitus (DM) have been poorly characterized. Some authors have reported normal pulmonary functions and even concluded that spirometry is not at all necessary in diabetic patients. Some studies have shown abnormal respiratory parameters in patients of DM. Moreover, the duration of DM and glycemic control have varied impact on the pulmonary functions.

**Aims and Objectives:** The study was undertaken to analyze the pulmonary function parameters in diabetic patients and compare them with age and gender matched healthy subjects. We correlated forced vital capacity (FVC) and forced expiratory volume in 1<sup>st</sup> second (FEV<sub>1</sub>) in diabetic patients with duration of the disease and glycosylated hemoglobin (HbA1c).

**Materials and Methods:** Pulmonary function tests (PFTs) were recorded in 60 type 2 diabetic male patients and 60 normal healthy male controls aged 40-60 years by using Helios 702 spirometer. The PFTs recorded were – FVC, FEV<sub>1</sub>, FEV<sub>1</sub>/FVC, and peak expiratory flow rate (PEFR). HbA1c of all the patients was also estimated. PFTs of diabetic patients and controls were compared by applying Student's unpaired *t* test. Associations between FVC and FEV<sub>1</sub> and HbA1c and duration of illness in diabetic patients were analyzed by applying Pearson's coefficient.

**Results:** The PFTs were significantly decreased in diabetic patients compared with the healthy controls except FEV<sub>1</sub>/FVC. There was no correlation found between FVC and FEV<sub>1</sub> and duration of illness as well as HbA1c.

**Conclusion:** DM being a systemic disease, which also affects lungs causing restrictive type of ventilatory changes probably because of glycosylation of connective tissues, reduced pulmonary elastic recoil and inflammatory changes in lungs. We found glycemic levels and duration of disease are probably not the major determinants of lung pathology, which requires further research.

**Keywords:** Diabetes, glycemic control, pulmonary function

---

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

---

## Introduction

The World Health Organization estimates that more than 180 million people worldwide have diabetes, and by 2030 it is expected that this number will have doubled. [1] There is an alarming increase in the incidence and prevalence of diabetes mellitus (DM) in Asian Indians. [2] Diabetes is a micro-macrovascular disorder with debilitating effects on many organs. Pulmonary complications of DM have been poorly characterized with conflicting results. The alveolar capillary network in the lung is a large micro-vascular unit and may be affected by microangiopathy. [3] However, because of its large reserve, substantial loss of the microvascular bed can be tolerated without developing dyspnoea. As a result, pulmonary diabetic micro-angiopathy may be under-recognized clinically. In DM pulmonary functions have been studied frequently in countries other than India, [4] while in our country there are few studies concerning these abnormalities and their relationship with glycosylated hemoglobin (HbA1c) and duration of the disease.

Reduced elastic recoil, reduced lung volume, diminished respiratory muscle performance, chronic low-grade inflammation, [5,6] decrease in pulmonary diffusion capacity for carbon monoxide, [7] autonomic neuropathy involving respiratory muscles [8] are some of the important changes occurring in DM.

Despite the unclear nature, the relationship between DM and pulmonary function tests (PFTs) remains important because of potential epidemiological and clinical implications. The loss of pulmonary reserve may become clinically important.

Hence, we hypothesized that PFTs are affected in DM in Indian population and the changes may correlate with HbA1c and the duration of the disease.

## Objectives

- The study aims to evaluate the PFTs in type 2 DM patients and compare them with the age and gender matched healthy controls.
- We also determine the co-relation of the HbA1c and duration of the disease with PFTs in type 2 DM patients.

## Materials and Methods

The study was carried out in 60 male patients of type 2 DM diagnosed by the treating physician, of the age group 40-60 years taking oral hypoglycemics, were randomly selected from the Diabetes Outpatient Department.

## Exclusion criteria

1. Patients having complaints of cough, sputum, or dyspnoea.
2. Smokers and patients with any cardio-respiratory illnesses or major diseases.

Sixty normal healthy males of the same age group and socioeconomic status were selected as control group. The controls were also thoroughly examined clinically. Those with cardio-respiratory, musculoskeletal, or endocrine diseases were excluded from the study.

Informed written consent was taken from patients as well as from controls. All the patients were handed a questionnaire that contained a detailed personal and medical history. PFTs of the patients as well as of the controls were performed with turbine flow sensor-based 702 Helios – Spirometer. All the tests were conducted according to American Thoracic Society/European Respiratory Society (ATS/ ERS guidelines) in a quiet room in sitting position. [9] The controls and patients performed spirometry three times at the interval of 15 minutes and the best of the three was taken into account. Parameters recorded were – forced vital capacity (FVC) in liters, forced expiratory volume in 1 second

(FEV<sub>1</sub>), FEV<sub>1</sub>/FVC in percentage (%), and peak expiratory flow rate (PEFR). For all these parameters percentage of predicted values for the respective age, height, and weight were taken into consideration.

Nearly 2 ml of venous blood was collected in ethylenediamine tetra acetic acid (EDTA) bulb in all the diabetic patients with aseptic precautions. HbA1c of all the patients was estimated as per the guidelines provided. [10]

All data were collected in a data collection form and then transferred to an Excel sheet by two independent data entry operators. Discrepant values were corrected by checking the data collection form. Clean data was then analyzed statistically.

PFTs of diabetic patients and controls were compared by applying Student's unpaired 't' test. Correlations between FVC and FEV<sub>1</sub> and HbA1c and duration of illness in diabetic

patients were analyzed by applying Pearson's coefficient. Statistical analysis was done by using SSPS version 11.

## Results

Table 1 depicts the physical characteristics of the normal controls as well as the patients of DM. Age, height, and weight of both the groups were comparable as statistically there was no difference between them ( $P > 0.05$ ). Our study showed that all the pulmonary parameters, that is, FVC, FEV<sub>1</sub>, and PEFR were significantly reduced except FEV<sub>1</sub>/FVC in patients of type 2 DM as compared with the healthy controls ( $P < 0.05$ ). The ratio FEV<sub>1</sub>/FVC is almost equal in normal controls and diabetic patients ( $P > 0.05$ ) [Table 2]. On correlating the FVC and FEV<sub>1</sub> with duration of illness and HbA1c, we found that there was no significant correlation between them ( $P > 0.05$ ) [Table 3].

**Table 1: Physical characteristics of subjects**

Parameter	DM patients, Mean±SD	Controls, Mean±SD	P Value
Age (Years)	53.90±8.45	54.88±8.28	>0.05
Height (cm)	159.23±7.86	161.28±7.33	>0.05
Weight (kg)	61.57±7.38	64.42±8.70	>0.05
HbA1C (%)	7.12±1.36	-	-
Duration DM (Years)	6.56±5.86	-	-

## Discussion

Our study showed that all the pulmonary parameters, that is, FVC, FEV<sub>1</sub>, and PEFR were significantly reduced except FEV<sub>1</sub>/FVC in patients of type 2 DM as compared with the healthy controls. This is in accordance with previous studies. [11-15]

Some of the prospective and cross-sectional studies have shown low vital capacity or restrictive pattern in type 2 DM. [16,17]

Meta-analysis by van den Borst, et al. showed that DM is associated with statistically

significant, impaired pulmonary function in a restrictive pattern. Moreover, these results were irrespective of body mass index (BMI), smoking, diabetes duration, and HbA1c levels. [18]

Uchida, et al. found that there was decreased pulmonary diffusing capacity in patients with diabetes with perfusion defect on ventilation perfusion scintigrams. [19] It was not possible for us to analyze the pulmonary diffusing capacity because of practical difficulties.

**Table 2: Comparison of PFTs in patients with type 2 DM and healthy controls**

Parameter	% predicted values	Control subjects Mean±SD	DM subjects Mean±SD	P value
FVC		89.36±9.71	77.97±12.99	<0.05*
FEV <sub>1</sub>		88.03±6.69	78.98±14.09	<0.05*
FEV <sub>1</sub> /FVC		111.36±10.62	112.83±9.35	>0.05
PEFR		77.70±12.81	59.16±99.35	<0.05*

Davis, et al. conducted a study in Western Australia in large number of patients of type 2 DM. They found that VC, FVC FEV<sub>1</sub>, and PEFR decreased at an average of between 1.1% and 3.1% of predicted values/year in type 2 DM patients.[11]

**Table 3: Correlation of HbA1c and duration of DM with PFTs**

Parameters	r <sup>2</sup>	P value
FVC with HbA1c	0.019	0.289
FEV <sub>1</sub> with HbA1c	0.007	0.498
FVC with duration	8.809e-0.009	0.9994
FEV <sub>1</sub> with duration	0.007	0.518

Ehrlich, *et al.* showed that patients with type 2 DM were at increased risk of several pulmonary condition like – asthma, Chronic Obstructive Pulmonary Disease (COPD), fibrosis, and pneumonia. [20]

Few studies have mentioned that no significant differences were observed in patients of type 2 DM. [21-23] Probably the small sample size is the reason behind these findings.

Pathophysiology of reduced lung function is still an interesting research issue. Normal lung mechanics and gas exchange are influenced by the integrity of the pulmonary connective tissue and microvasculature. Acceleration of aging process in connective tissue cross links and presence of nonenzymatic glycosylation and modification of alveolar surfactant action causes reduction in PFTs. [3] There have been reports of histopathological changes in the diabetic patients. In the study by Weynand *et al.*, [24] it was found that alveolar epithelium, endothelium capillary, and basal laminae were thickened in lungs on electron microscopy, when compared with the controls. In addition, the thickening of basal laminae was of the same magnitude in lung

and kidney. Diabetic microangiopathy might be existing in the pulmonary vascular bed. Moreover, reduced pulmonary capillary blood volume was found, favoring the evidence of microangiopathy. This could lead to redistribution of the pulmonary circulation, resulting in well ventilated areas to become underperfused. [25]

The thorax and lungs are rich in collagen and elastin. Stiffening of thorax and lung parenchyma can occur because of nonenzymatic glycosylation of these structural compounds. This may lead to restrictive pattern.[3] In our studies, since the FVC/FEV<sub>1</sub> ratio is statistically not significantly different in DM patients as compared with normal controls, other PFT values are lower in DM patients; this strongly suggests restrictive pattern in DM patients.

Studies have even shown diabetic polyneuropathy, which affects respiratory neuromuscular function and thus reducing pulmonary volumes. [26]

On correlating the FVC and FEV<sub>1</sub> with duration of illness and HbA1c, we found that there was no significant correlation between them [Table 3, Figures 1 and 2].

There are certain studies showing no correlation between HbA1c and PFTs. [7,14,22] They argued that HbA1c levels are indicators of glycemic control for a short period of 1-2 months, it was not adequate to conclude that the plasma glucose level was not related to decreased PFTs. While some studies have shown that the decline in PFTs was negatively correlated with HbA1c. [11,13]

There are studies that have reported no significant correlation between PFTs and duration of diseases, [22] while some of the studies have reported a strong negative correlation of PFTs with duration. [14,15] Since DM is a disease, which involves multiple organs randomly, the study of the effect of duration of the disease on them requires further research.

Several studies have analyzed the association between impaired lung function and death and found that a 10% decrease in FEV<sub>1</sub> was associated with a 12% increase in all-cause mortality in type 2 DM. [27]

### Clinical implications

Pulmonary dysfunction should be regarded as a specific derangement induced by DM. Further studies may clarify whether this should be included as a long-term complication of diabetes. The role of strict glycemic control on pulmonary function in diabetic patients is another interesting aspect and needs further studies. The impairment in PFTs can lower the threshold for clinical manifestations of acute or chronic lung disease. Patients with DM admitted with pneumonia have increased risk of complications and mortality. [28,29]

### Summary and Conclusion

DM being a systemic disease, also affects lungs causing restrictive type of ventilatory changes probably because of glycosylation of connective tissues, reduced pulmonary elastic recoil, and inflammatory changes in lungs. We found that glycemic levels and duration of

disease are probably not the major determinants of lung pathology, which requires further research.

### References

1. World Health Organization. Fact sheet: Diabetes. No. 312, November 2008. Available from: <http://www.who.int/mediacentre/factsheets/fs312/en/index.html>. [Last accessed on 2009 Apr 14].
2. King H, Aubert RE, Herman WH. Global burden of diabetes 1995 to 2025. Prevalence, numerical estimates and projections. *Diabetes Care* 1998; 21:14-31.
3. Sandler M. Is the lung is target organ in diabetes mellitus? *Arch Intern Med* 1990; 150:1385-8.
4. Klein OL, Krishnan JA, Jlick S, Smith LJ. Systematic review of association between lung function and type 2 diabetes mellitus. *Diabet Med* 2010; 27:977-87.
5. Hamlin CR, Kohn RR, Luschin JH. Apparent accelerated aging of human collagen in diabetes mellitus. *Diabetes* 1975; 24:902-4.
6. Fogarty AW, Jones S, Britton JR, Lewis SA, McKeever TM. Systemic inflammation and decline in lung function in a general population: A prospective study. *Thorax* 2007; 62:515-20.
7. Mori H, Okubo M, Okamura M, Yamane K, Kado S, Egusa G, *et al.* Abnormalities of pulmonary function in patients with non-insulin dependent diabetes mellitus. *Intern Med* 1992; 31:189-93.
8. Williams JG, Morris AI, Hayter RC, Ogilvie CM. Respiratory responses of diabetics to hypoxia, hypercapnia and exercise. *Thorax* 1984; 39:529-34.
9. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, *et al.* Standardization of spirometry. *Eur Respir J* 2005; 26:319-38.
10. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated haemoglobin assay. *N Engl J Med* 1984; 310:341-6.

11. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes, the fremantle diabetes study. *Diabetes Care* 2004; 27:752-7.
12. Asanuma Y, Fujiya S, Ide H, Agishi Y. Characteristics of pulmonary function in patients with diabetes mellitus. *Diabetes Res Clin Pract* 1985; 1:95-101.
13. Lange P, Groth S, Kastrup J, Mortensen J, Appleyard M, Nyboe J, *et al.* Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. *Eur Respir J* 1989; 2:14-9.
14. Barrett-Conor E, Frette C. NIDDM, impaired glucose tolerance, and pulmonary function in older adults. *Diabetes Care* 1996; 19:1441-4.
15. Davis TM, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its association in type 2 diabetes: The fremantle diabetes study. *Diabetes Res Clin Pract* 2000; 50:153-9.
16. Engstrom GJ, Janzon L. Risk of developing diabetes is inversely related to lung function: A population-based cohort study. *Diabet Med* 2002; 19:167-70.
17. Yeh HC, Punjabi NM, Wang NY, Pankow J, Duncan BB, Cox CE, *et al.* Cross sectional and prospective study of lung function in adults with diabetes mellitus. *Diabetes* 2002;51: A242-3.
18. Borst BB, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in Diabetes: A Metaanalysis. *Chest* 2010; 138:393-406.
19. Uchida K, Takahashi K, Aoki R, Ashitaka T. Ventilation-perfusion scintigram in diabetics. *Ann Nucl Med* 1991; 5:97-102.
20. Ehrlich SF, Quesenberry CP, Vanden Eeden SK, Shan J, Ferrara A. Patients diagnosed with diabetes are at increased risk for asthma, COPD, pulmonary fibrosis and pneumonia but not lung cancer. *Diabetes Care* 2010; 33:55-60.
21. Shan-ping J, Li-wen H, Yi-qun L, Guo-juan L, He-lin D, Yan L, *et al.* Pulmonary function in patients with diabetes mellitus. *Chin J Pathophysiol* 2005; 21:574-9.
22. Benbassat CA, Stern E, Kramer M, Lebzelter J, Blum I, Fink G. Pulmonary function in patients with diabetes mellitus. *Am J Med Sci* 2001; 322:127-32.
23. Sinha S, Guleria R, Misra A, Pandey RM, Yadav R, Tiwari S. Pulmonary functions in patients with type 2 diabetes mellitus and correlation with anthropometry and microvascular complications. *Indian J Med Res* 2004; 119:66-71.
24. Weynand B, Jonkheree A, Frans A, Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. *Respiration* 1999; 66:14-9.
25. Sandler M, Bunn AE, Stewart RI. Cross section study of pulmonary function in patients with insulin-dependent diabetes mellitus. *Am Rev Respir Dis* 1987; 135:223-9.
26. Kabitz HJ, Sonntag F, Walker D. Diabetic polyneuropathy is associated with respiratory muscle impairment in type 2 diabetes. *Diabetologia* 2008; 51:191-7.
27. Knuiman MW, James AL, Diviniti ML, Ryan G, Bartholomew HC, Musk AW. Lung function, respiratory symptoms, and mortality: Results from the buselton health study. *Ann Epidemiol* 1999; 9:297-306.
28. Khan A., Tidman D. M. M., Shakir D. S., & Darmal D. I. Breast Cancer in Afghanistan: Issues, Barriers, and Incidence. *Journal of Medical Research and Health Sciences*, 2022;5(8), 2125–2134.
29. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: A population-based case control study. *Diabetes Care* 2008; 31:1541-5.